A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability and pharmacokinetics of multiple ascending subcutaneous doses of MOR106 for 4 weeks, in adult Japanese subjects with moderate to severe atopic dermatitis.
Latest Information Update: 19 Dec 2021
At a glance
- Drugs MOR 106 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Acronyms Angelfish
- Sponsors Galapagos NV
- 19 Dec 2021 Planned End Date changed from 31 Dec 2020 to NULL.
- 19 Dec 2021 Planned initiation date changed from 19 Jun 2019 to NULL.
- 19 Dec 2021 New trial record